Greg Moeck Email

VP, Microbiology . VenatoRx Pharmaceuticals

Malvern, PA

Location

m****@venatorx.com

Primary Email

Current Roles

Employees:
77
Revenue:
$15.5M
About
Led by a world-class team of pharmaceutical veterans, VenatoRx is a private pharmaceutical company that is developing a new wave of anti-infective products to address increasing medical needs. VenatoRx's lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. Early clinical studies of cefepime/VNRX-5133 have been completed and VenatoRx plans to start Phase 3 pivotal trials in the second half of 2018. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents.
VenatoRx Pharmaceuticals Address
74 E. Swedesford Road
Malvern, PA
United States
VenatoRx Pharmaceuticals Email
VenatoRx Pharmaceuticals Phone Numbers
610-644-8935

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.